Skip to main content
Essex Bio-Technology Limited logo

Essex Bio-Technology Limited — Investor Relations & Filings

Ticker · 1061 HKEX Manufacturing
Open in API
Filings indexed 849 across all filing types
Latest filing 2024-12-10 Transaction in Own Shar…
Country HK Hong Kong
Listing HKEX 1061

About Essex Bio-Technology Limited

http://www.essexbio.com

Essex Bio-Technology Limited is a bio-pharmaceutical company specializing in the development, manufacture, and commercialization of genetically engineered therapeutic Fibroblast Growth Factors (FGFs), particularly recombinant bovine basic FGF (rb-bFGF). The company utilizes recombinant DNA technology to produce biologic drugs aimed at the treatment and healing of surface and organ wounds. Its portfolio includes six flagship biologics approved for a wide range of indications across key therapeutic areas: Ophthalmology, Dermatology, and Wound Healing. Leveraging an in-house R&D platform focused on growth factors and antibodies, the company maintains an active pipeline of projects. Its commercial reach extends to over 14,100 hospitals, supported by 46 regional sales offices.

Recent filings

Filing Released Lang Actions
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange Next Day Disclosure Return (Form FF305) detailing changes in issued shares, treasury shares, share repurchases and on-market sales of treasury shares pursuant to Main Board/GEM listing rules. It is not an earnings release, AGM material, or annual/interim report, but specifically reports the company’s own share transactions. This matches the definition of Transaction in Own Shares (Code: POS).
2024-12-10 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange "Next Day Disclosure Return" (Form FF305) detailing changes in issued shares, share repurchases, and on-market sales of treasury shares by the issuer. It is a real-time regulatory report of the company’s transactions in its own shares, matching the definition for Transaction in Own Shares (POS).
2024-12-04 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2024
Regulatory Filings Classification · 1% confidence The document is a Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules,” providing detailed month-end movements in share capital, issued shares, treasury shares, options and repurchases. It is a periodic regulatory submission to the HKEX rather than a standalone annual or interim financial report, earnings release, share issue announcement or management presentation. It therefore falls under general Regulatory Filings (RNS).
2024-12-03 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is an FF305 “Next Day Disclosure Return” under the Hong Kong Stock Exchange listing rules, detailing changes in issued shares and treasury shares – specifically share repurchases (20,000 shares at HKD 2.78). This is a mandated disclosure of the company’s own share transactions. Therefore, it fits the “Transaction in Own Shares” category.
2024-11-28 English
NEXT DAY DISCLOSURE RETURN
Transaction in Own Shares Classification · 1% confidence The document is a Hong Kong Stock Exchange ‘Next Day Disclosure Return’ (Form FF305) detailing changes in issued shares and treasury shares, specifically reporting share repurchases and cancellations. This is a report of transactions in the company’s own shares (buybacks). It does not announce a new report, dividend, merger, or management change. It clearly falls under Transaction in Own Shares (POS).
2024-11-27 English
NEXT DAY DISCLOSURE RETURN
Regulatory Filings
2024-11-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.